Harnessing more of the immune system for better cancer outcomes
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to truly therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
The programs in our pipeline stem from our deep understanding of NK cells and unique screening approaches that exploit their innate anti-tumor biology.
See our progress
latest in the media
interested in our research?
connect with us
Congratulations to our CSO for winning the 2019 Jacques Miller Medal
Join us @ Keystone! March 24-28 Innate and Non-Classical Immune Cells in Cancer Immunotherapy
31st Annual Lorne Cancer Conference
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
See the strategy
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are